AstraZeneca PLC (AZN.L)
AZN.L on London Stock Exchange
6,130.00GBp
14 Dec 2018
6,130.00GBp
14 Dec 2018
Change (% chg)
28.00 (+0.46%)
28.00 (+0.46%)
Prev Close
6,102.00
6,102.00
Open
6,083.00
6,083.00
Day's High
6,158.00
6,158.00
Day's Low
6,070.00
6,070.00
Volume
1,625,903
1,625,903
Avg. Vol
1,927,199
1,927,199
52-wk High
6,432.48
6,432.48
52-wk Low
4,544.50
4,544.50
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 1.38 | December | 17 Dec 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 7 | 9 | 8 | 7 |
| (2) OUTPERFORM | 9 | 9 | 10 | 10 |
| (3) HOLD | 8 | 7 | 6 | 6 |
| (4) UNDERPERFORM | 2 | 3 | 4 | 4 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.19 | 2.14 | 2.21 | 2.26 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 11 | 6,504.20 | 7,145.00 | 6,063.00 | 6,026.04 |
| Quarter Ending Mar-19 | 3 | 5,444.51 | 5,480.00 | 5,426.52 | 5,532.73 |
| Year Ending Dec-18 | 26 | 22,098.70 | 23,072.80 | 20,634.00 | 22,080.60 |
| Year Ending Dec-19 | 26 | 23,571.10 | 25,602.00 | 21,662.00 | 23,637.30 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 10 | 1.38 | 1.69 | 0.90 | 0.97 |
| Quarter Ending Mar-19 | 3 | 0.84 | 0.97 | 0.77 | -- |
| Year Ending Dec-18 | 27 | 3.40 | 3.60 | 3.28 | 3.68 |
| Year Ending Dec-19 | 27 | 3.84 | 4.50 | 3.21 | 4.18 |
| LT Growth Rate (%) | 3 | 7.57 | 13.20 | 4.51 | 3.88 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Sep-18 | 5,302.97 | 5,340.00 | 37.03 | 0.70 |
| Quarter Ending Jun-18 | 4,822.20 | 5,155.00 | 332.80 | 6.90 |
| Quarter Ending Mar-18 | 5,282.61 | 5,178.00 | 104.61 | 1.98 |
| Quarter Ending Dec-17 | 5,473.40 | 5,777.00 | 303.60 | 5.55 |
| Quarter Ending Sep-17 | 5,972.46 | 6,232.00 | 259.54 | 4.35 |
| Earnings (per share) | ||||
| Quarter Ending Sep-18 | 0.70 | 0.71 | 0.01 | 1.00 |
| Quarter Ending Jun-18 | 0.71 | 0.69 | 0.02 | 2.69 |
| Quarter Ending Mar-18 | 0.60 | 0.48 | 0.12 | 20.19 |
| Quarter Ending Dec-17 | 0.84 | 1.30 | 0.46 | 54.91 |
| Quarter Ending Sep-17 | 1.07 | 1.12 | 0.05 | 4.22 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 6,504.20 | 6,629.26 | 6,511.46 | 6,495.88 | 6,026.04 |
| Quarter Ending Mar-19 | 5,444.51 | 5,551.17 | 5,613.50 | 5,784.00 | 5,532.73 |
| Year Ending Dec-18 | 22,098.70 | 22,145.30 | 22,143.10 | 22,363.60 | 22,080.60 |
| Year Ending Dec-19 | 23,571.10 | 23,661.90 | 23,713.50 | 23,841.40 | 23,637.30 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 1.38 | 1.38 | 1.38 | 1.21 | 0.97 |
| Quarter Ending Mar-19 | 0.84 | 0.84 | 0.88 | 0.93 | -- |
| Year Ending Dec-18 | 3.40 | 3.41 | 3.42 | 3.40 | 3.68 |
| Year Ending Dec-19 | 3.84 | 3.84 | 3.83 | 3.88 | 4.18 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Dec-18 | 0 | 2 | 1 | 3 |
| Quarter Ending Mar-19 | 0 | 1 | 0 | 1 |
| Year Ending Dec-18 | 0 | 4 | 2 | 8 |
| Year Ending Dec-19 | 0 | 4 | 2 | 7 |
| Earnings | ||||
| Quarter Ending Dec-18 | 0 | 1 | 0 | 2 |
| Quarter Ending Mar-19 | 0 | 1 | 0 | 1 |
| Year Ending Dec-18 | 0 | 2 | 3 | 5 |
| Year Ending Dec-19 | 0 | 3 | 3 | 6 |
Earnings vs. 
Estimates- UPDATE 1-Poor China data caps turbulent week for FTSE 100 as investors rush for exits
- UPDATE 1-Moderna, largest biotech to go public, fails to impress in market debut
- Moderna, largest biotech to go public, fails to impress in market debut
- CORRECTED-UPDATE 1-AstraZeneca's Imfinzi fails to meet main goals in head and neck cancer study
- AstraZeneca's Imfinzi fails to meet main goals in head and neck cancer study
- What does AstraZeneca plc's deal with Pfizer mean for shareholders?
- Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after today’s update?
- 3 stocks to help you retire early
- Is it time to take profits on GlaxoSmithKline plc and AstraZeneca plc?
- These FTSE 100 stars have exploded in Q3! And they're not finished yet
- Why now is the perfect time to buy these 3 super income stocks